Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

Aceto Corporation company was founded in 1947 and is headquartered in Lake Success, New York. Aceto Corporation, together with its subsidiaries, engages in sourcing, quality assurance, regulatory support, marketing, and distributing chemically derived pharmaceuticals, biopharmaceuticals, specialty chemicals, and crop protection products. It operates in three segments: Health Sciences, Chemicals and Colorants, and Crop Protection. The Health Sciences segment offers active ingredients for generic pharmaceuticals, vitamins, and nutritional supplements, as well as products used in preparing pharmaceuticals primarily by drug companies and biopharmaceuticals. The Chemicals and Colorants segment offers specialty chemicals used in plastics, resins, adhesives, coatings, food, flavor additives, fragrances, cosmetics, metal finishing, electronics, and air-conditioning systems. This segment's products include dye and pigment intermediates, which are used in the color-producing industries, such as textiles, inks, paper, and coatings; and organic intermediates used in the production of agrochemicals. The Crop Protection segment provides herbicides, fungicides, and insecticides that control weed growth, as well as control the spread of insects and other micro organisms that damage plant growth. This segment also offers a sprout inhibitor for potatoes and an herbicide for sugar cane. Aceto Corporation serves a range of companies in the pharmaceutical, agricultural, color, surface coating/ink, general chemical consuming, and health science industries in the United States, Europe, and the Asia-Pacific.

Founded in the early 1900s, LEO Pharma has about two dozen products on the market, many of which treat psoriasis, eczema, and skin infections. The company's other focus areas include developing and manufacturing treatments for blood clot disorders, kidney disease, and support drugs for cancer treatments. Products such as Daivobet, Innohep, and Xamiol are among its best sellers. LEO Pharma has operations in Europe, as well as in the US, Middle East, Africa, and Asia. The company is wholly-owned by the Leo Foundation, which is managed by members of LEO Pharma's executive team.

Zeltia SA is a Spain-based holding company primarily engaged, through its subsidiaries, in the chemical and pharmaceutical sectors. Its main subsidiaries are: PharmaMar SA, biopharmaceutical company committed to advancing the treatment of cancer; Noscira SA, engaged in the research and development of innovative drugs for diseases of the nervous system; Genomica SAU, specializes in molecular diagnosis; Sylentis SAU, focused on the discovering and developing new therapeutic approaches based on gene silencing techniques; Zelnova SA, which produces and markets cleaning products for household and cetring sectors; and Xylazel SA, producer of paints, varnishes, wood and metal protectors for the industrial sector.

BioSante Pharmaceuticals, Inc. company was founded in 1996 and is based in Lincolnshire, Illinois. BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. It develops calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. The company's products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies.

Takeda San Diego develops high-throughput protein crystallography systems used to speed up the drug discovery process. The company's technology can detect the three-dimensional shape of proteins, an important step in determining how a drug can be attached to a protein to produce a therapeutic effect. The US biotech developer is one of Japanese drug maker Takeda's main research and development facilities. The subsidiary's drug discovery know-how is being used to develop new therapies for metabolic diseases such as diabetes, cancer, and inflammatory conditions.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.